STOCKHOLM & RADNOR, Pa. / Dec 30, 2024 / Business Wire / Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer... Read More

ZTALMY ® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to... Read More

Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic... Read More

RADNOR, Pa. / Oct 17, 2024 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data... Read More

New U.S. patent issued for ZTALMY ® (ganaxolone) oral titration regimens cover the treatment of a range of epilepsy disorders, expiring September 2042 Marinus continues to grow its IP portfolio to protect its scientific innovation RADNOR, Pa. / Oct 15, 2024 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure... Read More

Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis ​​on the management of SE RADNOR, Pa. / Oct 09, 2024 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3... Read More

RADNOR, Pa. / Oct 08, 2024 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 9,800 shares of... Read More

Enrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with NDA filing targeted for April 2025 TrustTSC maintained a double-blind discontinuation rate of 6.2% with 93% of patients continuing to the open-label extension Patients who completed Marinus’ Phase 2 TSC trial and entered the long-term extension demonstrated a median reduction in... Read More

RADNOR, Pa. / Sep 12, 2024 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced agenda topics and speakers for its upcoming Investor & Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. ET in New York. The event will feature presentations from Marinus’ leadership and key... Read More

RADNOR, Pa. / Sep 10, 2024 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET. A link to the event can be accessed on the Investors and... Read More

RADNOR, Pa. / Aug 19, 2024 / Business Wire / Marinus Pharmaceuticals , Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will feature presentations from Marinus management and key opinion leaders with a... Read More

ZTALMY ® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation... Read More

RADNOR, Pa. / Jul 30, 2024 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update... Read More

RADNOR, Pa. / Jul 18, 2024 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of epileptic seizures in patients two years of age and older with CDKL5 deficiency disorder... Read More

RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia Marinus will continue to prioritize the ZTALMY ® franchise and expansion opportunities in highly refractory, chronic epilepsies with Phase... Read More

Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC RADNOR, Pa. / May 17, 2024 / Business Wire / Marinus Pharmaceuticals , Inc . (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in the global... Read More

ZTALMY ® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million Enrollment to be completed mid-May in the Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 Topline results from the Phase 3 RAISE trial expected early summer 2024 Cost reduction... Read More

RADNOR, Pa. / May 02, 2024 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference. The fireside chat will take place on... Read More

RADNOR, Pa. / May 01, 2024 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024. The press release will be available on Marinus’ investor relations website at... Read More

Trial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future development of IV ganaxolone in refractory status epilepticus to be assessed following review of the final RAISE results Enrollment in the TrustTSC trial expected to complete mid-May with topline data on track for the first half of Q4... Read More

RADNOR, Pa. / Apr 05, 2024 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 47,400 shares of... Read More

RADNOR, Pa. / Mar 27, 2024 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,110,100 from Ovid Therapeutics, Inc. filed on March 26, 2024. This challenge relates to... Read More

Phase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024 Phase 3 TrustTSC trial approximately 85% enrolled with topline data now expected in first half of Q4 2024 ZTALMY ® (ganaxolone) net product revenue of $6.6 million for Q4 2023 and $19.6 million for the full year ended December 31, 2023 Full year 2024 U.S.... Read More

RADNOR, Pa. / Feb 21, 2024 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present at and participate in the following conferences in March. The TD Cowen 44 th Annual Healthcare Conference in Boston, MA Panel Discussion: Orphan Epilepsies - March 6 at 10:30 a.m.... Read More

RADNOR, Pa. / Feb 20, 2024 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on March 5, 2024. The Company will host a conference call at 4:30 p.m. E.T. on March 5, 2024, to provide a... Read More

RADNOR, Pa. / Feb 16, 2024 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 64,425 shares... Read More

RADNOR, Pa. / Jan 04, 2024 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 12,150 shares of... Read More

ZTALMY ® (ganaxolone) Q4 2023 preliminary net product revenue of between $6.5 and $6.7 million; full year 2023 preliminary net product revenue of between $19.5 and $19.7 million Projected full year 2024 U.S. ZTALMY net product revenue of between $32 and $34 million Over 90% of patients required for the interim analysis are now enrolled in the RAISE trial TrustTSC trial enrollment now over 70%; enrollment completion... Read More

RADNOR, Pa. / Dec 07, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 74,650 shares... Read More

Epilepsia publishes two-year open-label extension Marigold trial data of ZTALMY ® (ganaxolone) oral suspension CV in patients with CDKL5 deficiency disorder (CDD) In preliminary results from a Phase 1 multiple ascending dose (MAD) study, the second generation ganaxolone formulation demonstrated linear kinetics through a wide dose range; further formulation development to continue using modified-release technology RADNOR, Pa.... Read More

RADNOR, Pa. / Nov 14, 2023 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference. The fireside chat will take place on Tuesday,... Read More

RADNOR, Pa. / Nov 09, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 14,325 shares of... Read More

ZTALMY is approved by the U.S. Food and Drug Administration and the European Commission for appropriate patients with CDKL5 deficiency disorder The program enables physicians to request ZTALMY for eligible patients in geographies where the product is not commercially available and as supported by local regulatory requirements RADNOR, Pa. / Nov 07, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a... Read More

ZTALMY ® (ganaxolone) Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus; if the trial meets pre-defined stopping criteria at the interim analysis, topline data now anticipated Q2 2024 Initiated the Marinus Access Program to... Read More

RADNOR, Pa. / Oct 24, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023. Participants... Read More

RADNOR, Pa. / Oct 06, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 57,185 shares... Read More

RADNOR, Pa. / Sep 21, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Cantor Global Healthcare Conference. The fireside chat will take place on Thursday,... Read More

RAISE trial enrollment trends have returned to anticipated levels; on track for topline data in the first quarter of 2024, assuming pre-defined stopping criteria for interim analysis are met Continued execution of commercial launch of ZTALMY ® (ganaxolone) with estimated net product revenue of between $5 and $5.2 million for the third quarter of 2023 Cash runway now expected into fourth quarter of 2024 with projected cash,... Read More

RADNOR, Pa. / Sep 12, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York. The Investor & Analyst Event will feature presentations by Marinus’ leaders... Read More

RADNOR, Pa. / Sep 06, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 46,275 shares... Read More

RADNOR, Pa. / Aug 17, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a hybrid Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York. The event will feature presentations from Marinus management and Key Opinion Leaders to discuss the... Read More

RADNOR, Pa. / Aug 11, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 43,050 shares... Read More

ZTALMY ® (ganaxolone) second quarter net product revenue of $4.2 million; 2023 net product revenue guidance increased to between $17 and $18.5 million European Commission approved ZTALMY in CDKL5 deficiency disorder Interim analysis for the Phase 3 refractory status epilepticus trial now expected Q1 2024 First patient dosed in MAD trial with second generation ganaxolone formulation New emergency IND dosing paradigm for super... Read More

ZTALMY is the first treatment approved by the European Commission for seizures associated with CDKL5 deficiency disorder in children and adolescents RADNOR, Pa. / Jul 31, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the European Commission (EC) has granted approval of... Read More

RADNOR, Pa. / Jul 27, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on August 10, 2023. Participants may... Read More

RADNOR, Pa. / Jul 13, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 22,050 shares of... Read More

RADNOR, Pa. / Jun 21, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040. The USPTO issued... Read More

RADNOR, Pa. / Jun 02, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 72,825 shares... Read More

The European Commission decision is expected within 67 days of the CHMP opinion RADNOR, Pa. / May 26, 2023 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion... Read More

RADNOR, Pa. / May 17, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. “Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience,” said Scott... Read More

ZTALMY ® (ganaxolone) first quarter U.S. net product revenue of $3.3 million Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of 2023 CHMP opinion for ZTALMY in CDKL5 deficiency disorder expected by end of May; European Medicines Agency communicated that the major objection related to the choice of regulatory starting material has been resolved Phase 3... Read More

RADNOR, Pa. / May 09, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 50,400 shares... Read More

RADNOR, Pa. / May 03, 2023 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in May. JMP Securities 2023 Life Sciences Conference in New York, NY May 15 at 3:30 p.m. E.T. RBC Annual Healthcare Conference in New... Read More

RADNOR, Pa. / Apr 27, 2023 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on May 11, 2023. Participants may access... Read More

RADNOR, Pa. / Apr 18, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. “With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board,”... Read More

RADNOR, Pa. / Apr 06, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 93,825 shares... Read More

RADNOR, Pa. / Mar 22, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut syndrome (LGS). This designation applies to the active moiety of... Read More

RADNOR, Pa. / Mar 07, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022. “2022 was a year of significant growth and execution for Marinus, underscored by the successful U.S. launch of... Read More

RADNOR, Pa. / Feb 13, 2023 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on March 7, 2023. Participants may... Read More

RADNOR, Pa. / Feb 10, 2023 / Business Wire / Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 5 new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 57,900 shares of... Read More

RADNOR, Pa. / Feb 07, 2023 / Business Wire / Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in February and March. SVB Securities Global Biopharma Conference (virtual) February 15 at 2:20 p.m. E.T. Cowen 43rd Annual Health... Read More

RADNOR, Pa. / Jan 30, 2023 / Business Wire / Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee. “Ms. Silverstein brings to our Board deep capital markets expertise and extensive corporate strategic planning, business... Read More

Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 20,400 shares of its common stock (the “Common Stock”) as... Read More

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY ® net product revenue for the fourth quarter and year ended December 31, 2022. “We are pleased with the successful launch of ZTALMY resulting from the strong commercial foundation established and look forward... Read More